Claim OwnershipThe Syneos Health Podcast
Subscribed: 66Played: 1,290
Subscribe
© 2024 The Syneos Health Podcast
Description
The Syneos Health Podcast Series dissects some of the most complex issues biopharma leaders are facing today. Our clinical and commercial experts provide time-tested solutions, as well as perspectives on the news of the day. Hosted by Jeff Stewart, a long-time industry consultant who has advised biopharma leaders on licensing, mergers and acquisitions, pricing and market access, commercialization and go-to-market strategies, each episode explores the challenges and considerations involved with bringing biopharmaceuticals to the market.
143 Episodes
Reverse
Alzheimer's disease is a challenging and devastating diagnosis that affects memory and cognitive skills, with no known way to predict, track, treat, or cure it effectively. In 2024, around 90 million people over the age of 65 will be living with Alzheimer's. Clinical trials for new treatments have faced high failure rates, partly because it's difficult to identify the right patients at the right stage of the disease. The potential solution to this dilemma might lie in AI, which could help ana...
Breast cancer is the most common type of cancer among women worldwide, and it can be treated with different modalities, such as surgery, chemotherapy, radiation, hormone therapy and targeted therapy. However, even after the primary treatment, some cancer cells may remain in the body and cause recurrence or metastasis. This is where adjuvant therapies come in: they are additional treatments that aim to reduce the risk of cancer coming back or spreading to other parts of the body.In this episod...
This is an exciting time in the development of new medicines to treat both rare and age-related eye diseases. But what is it like in the trenches to develop and deliver clinical trials that evaluate both the safety and efficacy of these potential new medicines for diseases of the eye?In this episode, Nick Kenny, Syneos Health CSO and interim podcast host, is joined by Eileen Schramm, Senior Clinical Trial Manager, and Nicole Curry, Senior Project Manager, both in the Syneos Health Ophthalmolo...
In March 2024, the FDA approved a groundbreaking gene therapy for children with a specific form of leukodystrophy, offering hope to those with no current care options. However, the approval came with a hefty price tag, making headlines as the most expensive medicine in the world at $3,500,000 per patient. With the cost of innovation so high, what can we do to de-risk development, ensure affordability and achieve equitable access to these potentially life-changing therapies for the long term?N...
After 7 years as the Syneos Health Podcast's founding and flagship host, Jeff Stewart is stepping down. Here, he reflects on his experience and bids farewell.It doesn't end here - stay tuned for new episodes with new host(s), coming soon!(Jeopardy! clip courtesy of Ken Jennings.)The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies be...
Patient assistance programs can make a huge difference for patients who need expensive medicines but can't afford them. In this episode, Jeff Stewart talks with Dave MacLeod, Managing Director, Value & Access at Syneos Health about the benefits and challenges of patient assistance programs, which provide free or low-cost medicines to eligible patients. They discuss how these programs can improve access, adherence, and outcomes, as well as the operational and regulatory issues involve...
The Inflation Reduction Act (IRA), signed into law by President Joe Biden in August 2022, brings significant changes to the U.S. pharmaceutical market as it rolls out over the next 10 years.Today we dive deep into the IRA with Tiffany McCaslin, Managing Director, Value, Access and Health Outcomes at Syneos Health. Drawing from her extensive background in healthcare policy and industry strategy, Tiffany offers invaluable insights into the practical implications of this landmark legislation for...
For the first time, the technology behind Wall Street and Formula One racing is being used in pharmaceuticals—and it’s offering unparalleled potential for innovation in clinical trial execution and healthcare delivery.In this episode, host Jeff Stewart is joined by Darren Coleman, the general manager of RxDataScience, a Syneos Health company, who discusses KX technology, the world’s fastest time series database and analytics engine, and how it is now being applied to improve clinical trial ef...
When it comes to launching a pharmaceutical product in today’s market—especially as an emerging company—strategic investment can make all the difference.Drawing from a recent study on investing for commercial success, Michael Sarshad, Managing Director in the Commercial Advisory Group at Syneos Health, discusses the key factors for successfully launching a drug in today's market; the importance of strategic investment, timing and team experience in exceeding launch forecasts; and the diverse ...
Age-related vision loss is a rising concern for our growing aging population. According to the most recent data published by the CDC, nearly 20 million Americans aged 40+ have been diagnosed with some form of age-related macular degeneration (AMD). By the age of 75, roughly 1 in 3 people living in the United States will have some form of AMD, and about 1 in 4 of those will have a vision-threatening, late-stage form of AMD. These statistics underscore the need for heightened public awareness a...
The FDA has finalized a rule that addresses how drug ads must be presented in TV and radio commercials. The rule, proposed in 2010 and now effective from May of this year, aims to provide clarity and guidelines for pharmaceutical companies in presenting side effects and contraindications in a balanced manner. But it’s still a 27-page document.Here, we’ll boil it down for you.Matthew Snodgrass, head of US Digital and Social Strategy at Syneos Health, sheds light on the 13-year journey from pro...
Nervousness and uncertainty surround the question of what Artificial Intelligence (AI) may mean for the future of work. How can we deploy AI transformation—thoughtfully—across an organization and help workforces see what the new models will signify and require of us?In the first episode in this series related to our 2024 Health Trends, host Jeff Stewart is joined by Celeste Mosby, Senior Vice President and General Manager of Syneos Health Learning Solutions, to discuss the challenges of manag...
October is National Depression and Mental Health Screening Month, with October 10th specifically recognized as World Mental Health Day. A recent study co-led by Harvard Medical School and the University of Queensland established that one out of every two people in the world will develop a mental health disorder in their lifetime. This staggering number underscores the critical need to reduce the stigma of mental health, and to make sure that people who are suffering understand the diverse hel...
Radiosensitizers have emerged as potential game-changers in head and neck cancer therapy. A diverse group of compounds, radiosensitizers enhance radiation therapy's impact on tumor cells. Ongoing research seeks radiosensitizers that augment radiotherapy's efficacy without increasing toxicity, offering exciting prospects for the APAC region and beyond.Our new APAC Edition host Lance Eminger, Executive Director of Business Development is joined by Dr. Juan Manuel Carrera, Senior Medical Directo...
One of the biggest trends making headlines and impacting the healthcare industry to date is the rising popularity of GLP-1 drugs. Initially developed for diabetes management, these products have recently gained traction for weight loss indications. But with promising efficacy and growing popularity, is the healthcare industry truly prepared for the challenges posed by these drugs becoming such a hot commodity in the market?Tom Albers, Vice President of Strategy at Syneos Health company Spheri...
In this episode of the Syneos Health Podcast, we embark on a journey into the metaverse – a revolutionary concept that's transforming the way we approach training and learning. As we delve into the world of the metaverse and its implications for healthcare training, Michael Shim, PharmD, National Director, Field Medical Affairs and Marie Latsa, PharmD, Community Medical Director at Syneos Health, will share their firsthand experiences with metaverse-based training for Medical Science Liaisons...
The emergency department (ER) can be a place of chaos, panic and infinite amounts of unpredictability. Not knowing what can come through the doors at any given time makes this environment impossible to foresee and prepare for. Because of this uncertainty, the ER (and its patients) can be a particularly challenging target for clinical trials. In this episode, Dr. Ruth Henrice-Desrosiers, Medical Director, Syneos Health joins the podcast to discuss critical aspects to be consid...
The game continues to change in biotech as continued macroeconomic uncertainty has far reaching implications for the future of the biopharma ecosystem. Biotechs can no longer operate toward the single goal of being acquired by, or of licensing their assets to, large pharma—and players may need to develop products further than in the past, and therefore strategic pathway optionality needs to be weaved into and maintained throughout product and corporate development. But with a multitude o...
What is the healthcare industry up against in terms of recruiting, hiring, and retention, in the increasingly competitive job markets of China, Korea and Japan? Leigh Householder and Sam Wilson, commercial solutions lead for APAC, Syneos Health, discuss how changing customer needs, evolving market dynamics and shifts in customer engagement continue to be challenges when recruiting top talent in the region.Learn more about 2023 Health Trends here.More Episodes in the 202...
In our previous episode, we covered how companies can harness the power of digital therapeutics to improve their brand’s value proposition. But what does it really take to get a clinically validated prescription digital product to market? Dr. Shaheen Lakhan, Chief Medical Officer, Click Therapeutics joins us on the second episode of our two-part series on digital therapeutics to discuss the diligence required to help regulators, health plans and payers, clinicians, and patients understan...
Comments
Download from Google Play
Download from App Store
United States